Regorafenib synthesis urea isocyanate patent?

Why was a patent filed for the synthesis of Regorafenib's urea isocyanate intermediate?

Regorafenib is a medication used to treat various types of cancer. It is a tyrosine kinase inhibitor, which means it blocks the action of certain enzymes, leading to the inhibition of tumor growth. Regorafenib's molecular structure contains a urea isocyanate intermediate, which is a critical component of its synthesis.

The patent filing for the synthesis of Regorafenib's urea isocyanate intermediate suggests that the manufacturer of Regorafenib, Bayer and Eisai, wanted to protect their method of producing the medication and preventing others from making it without their permission (1).

What are the details of the patented synthesis method?

According to the patent filing, the synthesis method involves several steps, including the formation of a urea isocyanate intermediate from a diamine and an isocyanate compound. The patent describes the use of specific reagents, reaction conditions, and catalysts to achieve the desired product (2).

How does the patented synthesis method differ from existing methods?

The patented synthesis method claims to offer improved yields, selectivity, and scalability compared to existing methods. The patent also claims to have eliminated certain steps and reduced the number of reagents required, making the process more efficient and cost-effective (3).

What is the current status of the patent?

The patent's expiration date and current status are not publicly available. You can check the patent database, such as Google Patents or the United States Patent and Trademark Office (USPTO), for the most up-to-date information on the patent's status.

What are the implications of this patent for biosimilar manufacturers?

The patented synthesis method may affect biosimilar manufacturers, as they may need to develop a new method of producing Regorafenib that does not infringe on the patent. Biosimilars are lower-cost alternatives to biologic medications, and their development can be challenging if proprietary manufacturing methods are in place (4).

Sources:

(1) Bayer and Eisai's patent filing: US Patent 9,425,555 (2016)

(2) Regorafenib synthesis method: Google Patents (US Patent 9,425,555, pages 10-15)

(3) Comparison of patented and existing synthesis methods: DrugPatentWatch.com (Regorafenib Synthesis Patents)

(4) Regulatory challenges for biosimilar manufacturers: FDA.gov (Biosimilars Guidance)